Webinar Overview

Webinar Overview

June 30, 2015

Early market access planning can speed up access to new treatments for patients. However, there must also be a balance to ensure the appropriate evidence has been established to show the benefits and risks of these treatments.  In Europe, there is an armamentarium of Early Access Schemes that can be used to support new healthcare treatments. This webinar will review the Early Access Schemes that are available and will review the stakeholders involved and their need for evidence and opportunities for communication. Adaptive pathways will be highlighted in particular. Case studies will also be discussed to communicate what evidence is seen as meaningful. Presenting with Dr. Susanne Michel from Evidera’s Payer Strategy Group, will be Paul Miller, member of the NICE Appraisal Committee, who will highlight the UK’s role in Early Market Access and NICE’s take on adaptive pathways.

Who Should Attend

Directors, senior managers and those responsible for the following areas:

  • Market Access
  • Evidence Generation / Planning
  • Marketing
  • Pricing and Reimbursement
  • HEOR
  • Product Development

Key Learning Objectives

After the webinar, attendees should be able to:

  • Comprehend the various Early Access Schemes available in Europe
  • Have a better understanding of Adaptive Pathways, its stakeholders and what evidence they like to see
  • Identify ways of engagement and communication with stakeholders
  • Understand the value driving evidence to build a strong evidence package to support early market access

Presenter Information

Susanne Michel, MD, Europe Practice Lead, Payer Strategy, Evidera
Paul Miller, Member NICE Appraisal Committee

Contact us to see a recording of this webinar

Presenters

Susanne Michel, MD, Europe Practice Lead, Payer Strategy, Evidera
Paul Miller, Member NICE Appraisal Committee